Cargando…

Efficacy and safety of reduced‐dose chemotherapy plus immunotherapy in patients with lung squamous cell carcinoma: A real‐world observational study

BACKGROUND: Recently, chemotherapy plus immunotherapy has achieved remarkable efficacy in lung squamous cell carcinoma (LUSC). However, some patients, especially frail people, cannot tolerate full‐dose chemotherapy in the real world. To reduce toxicity, appropriate dose reduction in chemotherapy is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouyang, Ganlu, Liu, Yanyang, Liu, Jiewei, Huang, Lin, Luo, Feng, Li, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557858/ https://www.ncbi.nlm.nih.gov/pubmed/37676094 http://dx.doi.org/10.1002/cam4.6478

Ejemplares similares

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
por: Liu, Stephen V., et al.
Publicado: (2022)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Fujimoto, Daichi, et al.
Publicado: (2021)

Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
por: Zhu, Lingling, et al.
Publicado: (2022)

Real-world safety and effectiveness analysis of low-dose preschool sesame oral immunotherapy
por: Chua, Gilbert T., et al.
Publicado: (2023)

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
por: He, Xiran, et al.
Publicado: (2020)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

Stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC)
por: Li, Chunguang, et al.
Publicado: (2022)

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: Chen, You-Yi, et al.
Publicado: (2021)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
por: Jing, Shao-Wu, et al.
Publicado: (2022)

Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
por: Jiang, Qi, et al.
Publicado: (2023)

Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers
por: Zhu, Ying, et al.
Publicado: (2021)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
por: Yang, Yafan, et al.
Publicado: (2023)

A real-world retrospective study of safety, efficacy, compliance and cost of combination treatment with rush immunotherapy plus one dose of pretreatment anti-IgE in Chinese children with respiratory allergies
por: Zhang, Pingping, et al.
Publicado: (2022)

Docetaxel Plus Nedaplatin or Carboplatin as Second-Line Chemotherapy for Advanced Lung Squamous Cell Carcinoma in Real-World Practice: A Single-Center Experience
por: Zhong, Jian, et al.
Publicado: (2023)

Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study
por: Cao, Guang, et al.
Publicado: (2022)

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
por: Kotaka, Saki, et al.
Publicado: (2023)

Radiotherapy Combined with Chemotherapy for Regional Lymph Node Recurrence in Gastric Cancer
por: Cai, Liang, et al.
Publicado: (2020)

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study
por: Wang, Rui, et al.
Publicado: (2022)

Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study
por: Qu, Jingjing, et al.
Publicado: (2022)

A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients
por: Yang, Lu-Ping, et al.
Publicado: (2019)

The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study
por: Jiang, Wenjuan, et al.
Publicado: (2022)

Cystitis and Utipro(®) Plus: Real-World Evidence
por: Kostev, Karel, et al.
Publicado: (2023)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study
por: Wang, Yinkui, et al.
Publicado: (2022)

The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma
por: Wang, Ying, et al.
Publicado: (2022)

Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer
por: Abbas, Waseem, et al.
Publicado: (2021)

Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study
por: Wu, Xiaoyue, et al.
Publicado: (2022)

Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
por: Ma, Ke, et al.
Publicado: (2023)

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study [Retraction]
Publicado: (2022)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
por: Elegbede, Anifat A., et al.
Publicado: (2021)

Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma
por: Zhai, Xiaoqian, et al.
Publicado: (2021)

Real-World Use of Immunotherapy for Hepatocellular Carcinoma
por: Sara, Amir, et al.
Publicado: (2023)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Statin Monotherapy and Statin plus Ezetimibe Combination in a Real-World Setting
por: Ezhov, Marat V., et al.
Publicado: (2023)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
por: Hu, Jiao, et al.
Publicado: (2022)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7p5mtod4pam6es6d4823l444ic